ARTICLE | Company News
FDA to discuss suvorexant NDA
April 4, 2013 11:43 PM UTC
FDA's Peripheral and Central Nervous System Drugs Advisory Committee will meet on May 22 to discuss an NDA from Merck & Co. Inc. (NYSE:MRK) for suvorexant to treat insomnia. Merck declined to disclose...